Profusa Targets $47.9B CRO Market with Lumee Tissue Oxygen Launch
Event summary
- Profusa launched its Lumee tissue oxygen monitoring system for contract research organizations (CROs) on January 16, 2026.
- The product targets the $47.9 billion CRO market, growing at 7% CAGR, with immediate revenue generation.
- Sean Givens appointed as Head of Government and Healthcare Research Business to lead commercialization efforts.
- Lumee system offers continuous, real-time tissue oxygenation measurement for preclinical and translational research.
The big picture
Profusa’s entry into the CRO market aligns with the industry’s shift toward real-time, predictive biological data to enhance drug development efficiency. The $47.9 billion CRO market, projected to grow at 7% CAGR, presents a significant opportunity for advanced biosensing platforms. This strategic move positions Profusa to capitalize on increasing R&D investment and regulatory momentum around NAMs, potentially reducing late-stage development risks for pharmaceutical clients.
What we're watching
- Market Adoption
- How quickly CROs integrate Lumee into existing study designs and whether this drives near-term revenue growth.
- Competitive Positioning
- Whether Profusa can differentiate its biosensing platform in a rapidly expanding CRO market.
- Regulatory Dynamics
- The pace at which new approach methodologies (NAMs) gain regulatory traction, influencing demand for real-time biosensing.
Related topics